Nomogram model based on γ-glutamyl transferase to albumin ratio predicts survival in hepatocellular carcinoma patients with transarterial chemoembolization treatment

Table 3 Baseline characteristics of high and low γ-glutamyl transferase to albumin ratio groups after propensity score matching, n (%)

Variables	Total	GAR-low	GAR-high	P value
Patients	512	256	256
Gender				0.798
Female	71 (0.14)	34 (0.13)	37 (0.14)
Male	441 (0.86)	222 (0.87)	219 (0.86)
Age ≥ 60 years	215 (0.42)	107 (0.42)	108 (0.42)	1
HBV	293 (0.57)	148 (0.58)	145 (0.57)	0.858
HCV	17 (0.03)	8 (0.03)	9 (0.04)	1
Alcohol	203 (0.40)	99 (0.39)	104 (0.41)	0.718
Diabetes	47 (0.09)	25 (0.1)	22 (0.09)	0.76
Hypertension	65 (0.13)	29 (0.11)	36 (0.14)	0.426
ALT levels ≥ 40, U/L	304 (0.59)	147 (0.57)	157 (0.61)	0.418
ALP levels ≥ 125, U/L	395 (0.77)	196 (0.77)	199 (0.78)	0.833
Serum AFP ≥ 500, ng/mL	221 (0.43)	108 (0.42)	113 (0.44)	0.721
Child-Pugh class				0.93
A	371 (0.72)	186 (0.73)	185 (0.72)
B	134 (0.26)	67 (0.26)	67 (0.26)
C	7 (0.01)	3 (0.01)	4 (0.02)
Lymph node metastasis	269 (0.53)	139 (0.54)	130 (0.51)	0.479
Extrahepatic metastasis	99 (0.19)	49 (0.19)	50 (0.20)	1
PVTT	232 (0.45)	125 (0.49)	107 (0.42)	0.131
BCLC stage				0.347
A	58 (0.11)	25 (0.10)	33 (0.13)
B	67 (0.13)	29 (0.11)	38 (0.15)
C	380 (0.74)	199 (0.78)	181 (0.71)
D	7 (0.01)	3 (0.01)	4 (0.02)
Number of tumors ≥ 2	385 (0.75)	192 (0.75)	193 (0.75)	1
Tumor diameter, cm				0.797
< 3	50 (0.10)	22 (0.09)	28 (0.11)	0.797
≥ 3, < 5	79 (0.15)	41 (0.16)	38 (0.15)
≥ 5, < 10	234 (0.46)	116 (0.45)	118 (0.46)
≥ 10	149 (0.29)	77 (0.30)	72 (0.28)

GAR-low: γ-glutamyl transferase to albumin ratio < 4.75; GAR-high: γ-glutamyl transferase to albumin ratio ≥ 4.75; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer.